Application of Hazard Function to Investigate Recurrence of Intrahepatic Cholangiocarcinoma After Curative-Intent Liver Resection: A Novel Approach to Characterize Recurrence.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
03
06
2022
accepted:
02
07
2022
pubmed:
28
8
2022
medline:
11
2
2023
entrez:
27
8
2022
Statut:
ppublish
Résumé
To investigate recurrence patterns after surgery for intrahepatic cholangiocarcinoma (ICC) relative to lymph node status, tumor extension, tumor burden score (TBS), and adjuvant chemotherapy. Patients who underwent curative-intent resection for ICC from 1990 to 2020 were enrolled from a multi-institutional database. The hazard function was applied to plot the hazard rates over time, with further stratification by T and N AJCC 8th edition categories, TBS, and adjuvant chemotherapy. A total of 1192 patients underwent curative-intent resection for ICC and 59.9% experienced recurrence. Overall, the peak of recurrence occurred at 6.6 months. Among patients with negative lymph nodes, the T4-category had a higher peak rate of recurrence (0.1199 at 10.2 months) compared with other T-categories, while high TBS had an earlier peak of recurrence (4.2 months) compared with lower TBS. Among patients with N1 disease, T2-T4 categories had multipeak patterns of recurrence with higher hazard rates during the first 3 years after surgery in comparison with T1-category, while patients with high TBS had an earlier (4.0 months) and higher hazard peak rate compared with lower TBS groups. The administration of adjuvant chemotherapy was associated with delayed hazard rates of recurrence for N1 (4 months) and NX (6 months) categories. The novel application of the hazard function to assess hazard rates and timing patterns of recurrence following resection for ICC demonstrated that recurrence varied based on T- and N-categories, as well as TBS. Hazard function-based recurrence data may be helpful to tailor counseling, surveillance, and adjuvant therapy recommendations.
Identifiants
pubmed: 36029379
doi: 10.1245/s10434-022-12463-7
pii: 10.1245/s10434-022-12463-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1340-1349Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. Society of Surgical Oncology.
Références
El-Diwany R, Pawlik TM, Ejaz A. Intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am. 2019;28(4):587–99.
doi: 10.1016/j.soc.2019.06.002
Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(7):1777–87.
doi: 10.1007/s00268-019-04966-4
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.
doi: 10.1016/j.jhep.2014.01.021
Tsilimigras DI, Sahara K, Wu L, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823–31.
doi: 10.1001/jamasurg.2020.1973
Choi WJ, Williams PJ, Claasen M, et al. Systematic review and meta-analysis of prognostic factors for early recurrence in intrahepatic cholangiocarcinoma after curative-intent resection. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11463-x .
doi: 10.1245/s10434-022-11463-x
Hess KR, Levin VA. Getting more out of survival data by using the hazard function. Clin Cancer Res. 2014;20(6):1404–9.
doi: 10.1158/1078-0432.CCR-13-2125
Kudose Y, Shida D, Ahiko Y, et al. Evaluation of recurrence risk after curative resection for patients with stage I to III colorectal cancer using the hazard function: retrospective analysis of a single-institution large cohort. Ann Surg. 2022;275(4):727–34.
doi: 10.1097/SLA.0000000000004058
Vollmer RT. The dynamics of death in prostate cancer. Am J Clin Pathol. 2012;137(6):957–62.
doi: 10.1309/AJCPJK9V9LUMUETV
Ishimaru K, Kawai K, Nozawa H, et al. Hazard function analysis of metastatic recurrence after colorectal cancer surgery—A nationwide retrospective study. J Surg Oncol. 2021;123(4):1015–22.
doi: 10.1002/jso.26378
Demicheli R, Hrushesky W, Retsky M, Biganzoli E. Interpreting breast cancer survival data by the hazard function: remarkable findings from event dynamics. Medicina. 2020;56(9):468.
doi: 10.3390/medicina56090468
Vega EA, Newhook TE, Kawaguchi Y, et al. Conditional recurrence-free survival after oncologic extended resection for gallbladder cancer: an international multicenter analysis. Ann Surg Oncol. 2021;28(5):2675–82.
doi: 10.1245/s10434-021-09626-3
Bagante F, Spolverato G, Merath K, et al. Intrahepatic cholangiocarcinoma tumor burden: a classification and regression tree model to define prognostic groups after resection. Surgery. 2019;166(6):983–90.
doi: 10.1016/j.surg.2019.06.005
Hu LS, Zhang XF, Weiss M, et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26(8):2549–57.
doi: 10.1245/s10434-019-07353-4
Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.
doi: 10.1200/JCO.2012.41.5984
Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines. Ann Surg Oncol. 2021;28(5):2660–74.
doi: 10.1245/s10434-021-09671-y
Zhang XF, Xue F, He J, et al. Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. HPB. 2021;23(9):1456–66.
doi: 10.1016/j.hpb.2021.02.009
Tsilimigras DI, Hyer JM, Paredes AZ, et al. Tumor burden dictates prognosis among patients undergoing resection of intrahepatic cholangiocarcinoma: a tool to guide post-resection adjuvant chemotherapy? Ann Surg Oncol. 2021;28(4):1970–8.
doi: 10.1245/s10434-020-09393-7
Bagante F, Spolverato G, Weiss M, et al. Defining long-term survivors following resection of intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2017;21(11):1888–97.
doi: 10.1007/s11605-017-3550-7
Strasberg SM, Belghiti J, Clavien PA, et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2(3):333–9.
doi: 10.1016/S1365-182X(17)30755-4
Amin MB ES, Greene FL, et al. American Joint Committee on Cancer. Springer; 2017.
Zhang XF, Xue F, Dong DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis. Ann Surg. 2021;274(6):e1187–95.
doi: 10.1097/SLA.0000000000003788
Li H, Liu R, Qiu H, et al. Tumor burden score stratifies prognosis of patients with intrahepatic cholangiocarcinoma after hepatic resection: A retrospective, multi-institutional study. Front Oncol. 2022;12:829407.
doi: 10.3389/fonc.2022.829407
Sasaki K, Morioka D, Conci S, et al. The tumor burden score: A new, “Metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. 2018;267(1):132–41.
doi: 10.1097/SLA.0000000000002064
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–75.
doi: 10.1016/S0140-6736(17)33326-3
Alfano CM, Mayer DK, Bhatia S, et al. Implementing personalized pathways for cancer follow-up care in the United States: Proceedings from an American Cancer Society-American Society of Clinical Oncology summit. CA Cancer J Clin. 2019;69(3):234–47.
doi: 10.3322/caac.21558
Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686–9.
doi: 10.1016/S0140-6736(02)08594-X
Clark TG, Bradburn MJ, Love SB, et al. Survival analysis part I: basic concepts and first analyses. Br J Cancer. 2003;89(2):232–8.
doi: 10.1038/sj.bjc.6601118
Dignam JJ, Dukic V, Anderson SJ, Mamounas EP, Wickerham DL, Wolmark N. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat. 2009;116(3):595–602.
doi: 10.1007/s10549-008-0200-5
Aalen OO, Gjessing HK. Understanding the shape of the hazard rate: a process point of view (with comments and a rejoinder by the authors). Stat Sci. 2001;16(1):1–22.
doi: 10.1214/ss/998929473
Singpurwalla ND. The hazard potential. J Am Stat Assoc. 2006;101(476):1705–17.
doi: 10.1198/016214506000001068
Rahnemai-Azar AA, Pandey P, Kamel I, Pawlik TM. Monitoring outcomes in intrahepatic cholangiocarcinoma patients following hepatic resection. Hepat Oncol. 2016;3(4):223–39.
doi: 10.2217/hep-2016-0009
Tsilimigras DI, Sahara K, Paredes AZ, et al. Predicting lymph node metastasis in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2021;25(5):1156–63.
doi: 10.1007/s11605-020-04720-5
Zhang XF, Lv Y, Weiss M, et al. Should utilization of lymphadenectomy vary according to morphologic subtype of intrahepatic cholangiocarcinoma? Ann Surg Oncol. 2019;26(7):2242–50.
doi: 10.1245/s10434-019-07336-5
Ke Q, Lin N, Deng M, Wang L, Zeng Y, Liu J. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: a systematic review and meta-analysis. PLoS One. 2020;15(2):e0229292.
doi: 10.1371/journal.pone.0229292
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.
doi: 10.1016/S1470-2045(18)30915-X